clinical trial · NCT06613100
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Amgen·phase1·recruiting·n = 40
Prostate CancerXaluritamigGnRH Antagonist
brief summary
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.
started
Nov 25, 2024
primary completion
Jan 22, 2027
completion
Jan 23, 2030
last updated
Dec 1, 2025
official title
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol